Beyond ruxolitinib in steroid-refractory acute graft-versus-host disease

Br J Haematol. 2021 Nov;195(3):306-307. doi: 10.1111/bjh.17735. Epub 2021 Aug 16.

Authors

Catherine J Lee¹, Iskra Pusic², Bipin N Savani³

Affiliations

¹ Utah Transplantation & Cellular Therapy Program, Huntsman Cancer Institute at University of Utah, Salt Lake City, UT, USA.
² Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
³ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

PMID: 34402041
DOI: 10.1111/bjh.17735

No abstract available

Publication types

Comment

MeSH terms

Graft vs Host Disease* / drug therapy
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Nitriles
Pyrazoles
Pyrimidines
Steroids / therapeutic use

Substances

Nitriles
Pyrazoles
Pyrimidines
Steroids
ruxolitinib